Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NST-628 in Advanced Solid Tumors with MAPK Pathway Alterations
NCT06326411Phase 1Recruiting
- Sponsor
- Nested Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2028
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nst-628 in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Nested Therapeutics. Primary endpoints: Safety and Tolerability at 1 year, Recommended Dose for Expansion at 28 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
nst-628
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)glioma
Beyond the preview
Go deeper on NCT06326411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326411.